Results 81 to 90 of about 34,211 (250)
Cardiac MRI for differentiating chemotherapy-induced cardiotoxicity in sarcoma and breast cancer
Radiology and OncologyOver the past few decades, many studies have focused on anthracyclines effect on the heart (cardiotoxicity), but only a few have focused on sarcoma.
Ibrahim El-Sayed H +5 more
doaj +1 more source
Cardiac toxicity of antineoplastic anthracyclines
, 2003 Anthracyclines play a major role in the treatment of solid malignancies, but their clinical use is limited by acute or chronic cardiac toxicity. This is not due to the same molecular action involved in the antineoplastic effect, i.e.
DANESI, ROMANO, ZUCCHI, RICCARDO
core +1 more source
, 2023 1. ABCB1 (P-glycoprotein, MDR1) is one of the most important transporter involved in cancer multi-drug resistance. It also plays a significant role in cancer resistance against anthracyclines, an anticancer group of drugs, including doxorubicin and ...
Kamil Piska (6541331) +5 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis +5 more
wiley +1 more source
Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma [PDF]
Objective: Anthracyclines can damage the left ventricle, causing cardiomyopathy. This study evaluated the protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma.
گلدوست, محمد +5 more
core
Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines [PDF]
, 2011 Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to a growing population of long-term childhood cancer survivors.
Steven E. Lipshultz +7 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum +5 more
wiley +1 more source
Control of Gemcitabine Activity With Blue and Red Light
Chemistry – A European Journal, EarlyView.Treating cancer with chemotherapy is generally associated with many side effects, which can be addressed by selectively releasing the desired drugs with visible light. Sixteen new blue light‐activatable cytostatics were introduced, with the gemcitabine derivative exhibiting ideal properties.
Nils F. Kersten +6 more
wiley +1 more source
Dose optimization of anthracyclines
, 1994 Despite the fact that anthracyclines are one of the most commonly used and active classes of anticancer agents and that their pharmacokinetic behavior has been extensively studied, optimal anthracycline dosage regimens have not. yet been defined.
de Valeriola, Dominique
core
ORIGINAL ARTICLE Childhood Malignancy and Cardiotoxicity of Anthracyclines
, 2012 Background: Anthracyclines are antitumor agents with broad spectrum activity against many childhood malignancies. An important side effect of these drugs is cardiotoxicity which may happen even years after discontinuation.
Assistant Professor, MD, Pediatric Rouhangiz Sorkhabi +14 more
core